DDX41 and infection: In the situation of secondary DENV infection, it was reported that group-reactive anti-E mAbs derived from patients after secondary DENV infection had higher binding avidity and neutralizing potency compared with those derived after primary infection, suggesting cross-reactive anti-E Abs (including group-reactive and complex-reactive Abs) evolved from low avidity and poor neutralizing after primary infection to high avidity and potent neutralizing after secondary infection (Tsai et al., 2013).